Current Assets
Restricted Cash
Vertex Pharmaceuticals Restricted Cash increased by 300.0% to $12M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.1%, from $10.7M to $12M. Over 5 years (FY 2020 to FY 2025), Restricted Cash shows an upward trend with a 33.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
Metric ID:
restricted_cashHistorical Data
19 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.5M | $5.1M | $3.9M | $1.9M | $5.5M | $8M | $5.7M | $2.3M | $6.4M | $3.2M | $11.4M | $10.9M | $8.9M | $2.6M | $10.7M | $9.8M | $8.2M | $3M | $12M |
| QoQ Change | — | +13.3% | -23.5% | -51.3% | +189.5% | +45.5% | -28.7% | -59.6% | +178.3% | -50.0% | +256.3% | -4.4% | -18.3% | -70.8% | +311.5% | -8.4% | -16.3% | -63.4% | +300.0% |
| YoY Change | — | — | — | — | +22.2% | +56.9% | +46.2% | +21.1% | +16.4% | -60.0% | +100.0% | +373.9% | +39.1% | -18.8% | -6.1% | -10.1% | -7.9% | +15.4% | +12.1% |
Range$1.9M – $12M
CAGR+24.4%
Avg YoY Growth+40.0%
Median YoY Growth+16.4%
Restricted Cash at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's restricted cash?
- Vertex Pharmaceuticals (VRTX) reported restricted cash of $12M in Q1 2026.
- How has Vertex Pharmaceuticals's restricted cash changed year-over-year?
- Vertex Pharmaceuticals's restricted cash increased by 12.1% year-over-year, from $10.7M to $12M.
- What is the long-term trend for Vertex Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's restricted cash has grown at a 33.8% compound annual growth rate (CAGR), from $700K to $3M.